Mizuho Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs (NASDAQ:ESTA) had its target price raised by research analysts at Mizuho from $90.00 to $100.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s target price suggests a potential upside of 24.96% from the stock’s current price.

ESTA has been the subject of several other research reports. Citigroup upped their price target on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Stephens boosted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday. Canaccord Genuity Group raised their target price on Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Needham & Company LLC lifted their price target on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, BTIG Research increased their price objective on Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $86.29.

Establishment Labs Price Performance

Shares of Establishment Labs stock traded up $0.36 on Wednesday, reaching $80.03. The company’s stock had a trading volume of 421,073 shares, compared to its average volume of 512,654. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06. The company has a market capitalization of $2.33 billion, a P/E ratio of -28.18 and a beta of 0.99. The stock has a 50-day moving average price of $70.99 and a 200-day moving average price of $57.73. Establishment Labs has a 52-week low of $26.56 and a 52-week high of $83.31.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The firm had revenue of $64.62 million for the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter last year, the company earned ($1.19) EPS. Analysts expect that Establishment Labs will post -2.41 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP acquired a new stake in Establishment Labs during the third quarter worth about $34,000. Kestra Advisory Services LLC purchased a new stake in shares of Establishment Labs in the 4th quarter valued at approximately $47,000. State of Wyoming acquired a new stake in shares of Establishment Labs during the 3rd quarter worth approximately $71,000. Osaic Holdings Inc. raised its position in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares during the period. Finally, CWM LLC raised its position in shares of Establishment Labs by 45.9% during the 2nd quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after buying an additional 686 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

Key Establishment Labs News

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q4 results beat estimates: ESTA reported a loss of $0.09/share versus consensus -$0.22 and revenue of $64.62M (up ~45% YoY), showing much narrower losses and stronger top-line momentum. Press Release
• Positive Sentiment: FY-2026 revenue guidance slightly above Street: management guided revenue of $264.0M–$266.0M versus consensus ~$263.2M, providing modest confirmation of continued growth. Q4 & Guidance Release
• Positive Sentiment: Analysts raised targets and reiterated buy ratings: BTIG bumped its target to $88 (buy) and Needham raised its target to $86 (buy), signaling increased analyst confidence and helping demand for the shares. Benzinga (BTIG & Needham coverage) TickerReport (Needham)
• Positive Sentiment: Company targets at least 25% revenue growth in 2026 and is expanding its minimally invasive platforms — a multi-year growth narrative that supports higher revenue expectations. MSN Article
• Neutral Sentiment: Leadership transition announced to support the next growth phase — management framed this as strategic for scale, but transitions can create short-term execution risk. Leadership Transition
• Neutral Sentiment: Full earnings call transcript is available for detail on margin trajectory, modality adoption and unit economics; useful for investors who want to dig into guidance assumptions. Earnings Call Transcript
• Negative Sentiment: Company remains unprofitable with negative net margin and a large negative ROE, meaning profitability and margin expansion are still key execution risks that could cap upside if not achieved. Zacks Coverage

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.